1:50AM Seattle Genetics highlights ADCETRIS Frontline HL and MTCL clinical development programs and antibody-drug conjugate collaborator data (SGEN) 34.32 : Seattle Genetics (SGEN) highlighted ongoing clinical development programs for ADCETRIS in frontline Hodgkin lymphoma and mature T-cell lymphoma and progress with collaborator antibody-drug conjugate. In addition, encouraging phase 1 data were presented from two ADC clinical programs being developed by Genentech, a member of the Roche Group (RHHBY), using Seattle Genetics technology.
Key findings presented in an oral presentation included:
Patients enrolled in the study were diagnosed with non-squamous NSCLC or non-mucinous platinum-resistant OC. All patients had non-curable, locally advanced or metastatic disease and were heavily pretreated, with a median of four or five prior systemic therapies. The median age of patients enrolled was 60.
Patients received a median of three doses ranging from 0.2 milligrams per kilogram (mg/kg) to 2.8 mg/kg on an every three week basis. A dose of 2.4 mg/kg was selected for the dose expansion cohort and determined to be the recommended phase 2 dose.
Among the 18 patients with OC treated at dose levels 1.8 to 2.4 mg/kg with IHC staining scores of 2+ or 3+, five patients (27%) had confirmed objective responses. In addition, one patient with NSCLC dosed at 1.8 mg/kg experienced a confirmed partial response.
Most adverse events were Grade 1 and 2. The most frequent adverse events at the recommended 2.4 mg/kg dose included fatigue, nausea, vomiting, headache and peripheral neuropathy. Peripheral neuropathy was manageable with dose delays and/or reductions in most patients.
